
Brokerage Stifel starts coverage on drug developer Palvella Therapeutics PVLA.O with "buy" rating and $45 PT
New PT represents a 65% upside to the stock's last close
Stifel thinks PVLA has the potential to build a portfolio of rare skin disease treatments, "which collectively could have multi-billion-dollar potential"
Stifel notes co's gel QTORIN optimizes for delivery of the treatment into the deepest regions of the skin with potency and high patient tolerability
Including session's moves, PVLA stock more than doubled YTD